Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Pyxis Oncology Analyst Ratings and Price Targets | NASDAQ:PYXS | Benzinga
Pyxis Oncology Inc has a consensus price target of $10.56 based on the ratings of 10 analysts. The high is $15 issued by EF Hutton on July 31, 2023. The low is $5 issued by HC Wainwright & Co. on March 19, 2025. The 3 most-recent analyst ratings were released by RBC Capital, HC Wainwright & Co., and HC Wainwright & Co. on March 19, 2025, March 19, 2025, and December 20, 2024, respectively. With an average price target of $6 between RBC Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 455.56% upside for Pyxis Oncology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
Stephens & Co.
Stifel
Jefferies
1calculated from analyst ratings
Analyst Ratings for Pyxis Oncology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | Buy Now | 640.74% | RBC Capital | Leonid Timashev47% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2025 | Buy Now | 362.96% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 362.96% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $7 → $5 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 640.74% | RBC Capital | Leonid Timashev47% | $10 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 11/21/2024 | Buy Now | 825.93% | RBC Capital | Leonid Timashev47% | $7 → $10 | Maintains | Outperform | Get Alert |
| 11/21/2024 | Buy Now | — | William Blair | Andy Hsieh20% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/21/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 1103.7% | Stephens & Co. | Sudan Loganathan31% | → $13 | Initiates | → Overweight | Get Alert |
| 09/19/2024 | Buy Now | 548.15% | RBC Capital | Leonid Timashev47% | $7 → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/16/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 825.93% | Stifel | Bradley Canino40% | → $10 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 825.93% | Jefferies | Farzin Haque57% | → $10 | Assumes | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 548.15% | RBC Capital | Leonid Timashev47% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 03/22/2024 | Buy Now | 548.15% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $4 → $7 | Maintains | Buy | Get Alert |
| 02/09/2024 | Buy Now | 640.74% | BTIG | Kaveri Pohlman25% | → $8 | Initiates | → Buy | Get Alert |
| 01/23/2024 | Buy Now | 1011.11% | Leerink Partners | Jeffrey La Rosa20% | → $12 | Initiates | → Outperform | Get Alert |
| 11/30/2023 | Buy Now | 270.37% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $4 | Initiates | → Buy | Get Alert |
| 09/05/2023 | Buy Now | 548.15% | RBC Capital | Leonid Timashev47% | → $7 | Initiates | → Outperform | Get Alert |
| 07/31/2023 | Buy Now | 1288.89% | EF Hutton | Tony Butler43% | → $15 | Initiates | → Buy | Get Alert |
| 03/23/2023 | Buy Now | 1196.3% | Credit Suisse | Tiago Fauth42% | → $14 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for Pyxis Oncology (PYXS) stock?
The latest price target for Pyxis Oncology (NASDAQ:PYXS) was reported by RBC Capital on March 19, 2025. The analyst firm set a price target for $8.00 expecting PYXS to rise to within 12 months (a possible 640.74% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pyxis Oncology (PYXS)?
The latest analyst rating for Pyxis Oncology (NASDAQ:PYXS) was provided by RBC Capital, and Pyxis Oncology reiterated their outperform rating.
When was the last upgrade for Pyxis Oncology (PYXS)?
There is no last upgrade for Pyxis Oncology
When was the last downgrade for Pyxis Oncology (PYXS)?
The last downgrade for Pyxis Oncology Inc happened on November 21, 2024 when William Blair changed their price target from N/A to N/A for Pyxis Oncology Inc.
When is the next analyst rating going to be posted or updated for Pyxis Oncology (PYXS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pyxis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pyxis Oncology was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.
Is the Analyst Rating Pyxis Oncology (PYXS) correct?
While ratings are subjective and will change, the latest Pyxis Oncology (PYXS) rating was a reiterated with a price target of $8.00 to $8.00. The current price Pyxis Oncology (PYXS) is trading at is $1.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.